BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miller MH, Ferguson MAJ, Dillon JF. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease: Performance of non-invasive biomarkers in non-alcoholic fatty liver disease. Liver International 2011;31:461-73. [DOI: 10.1111/j.1478-3231.2011.02451.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Baker SS, Baker RD, Zhu R, Zhu L. Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism. PLoS One 2012;7:e51131. [PMID: 23300535 DOI: 10.1371/journal.pone.0051131] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
2 Gluud LL, Knop FK, Vilsbøll T. Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. BMJ Open. 2014;4:e005325. [PMID: 25526792 DOI: 10.1136/bmjopen-2014-005325] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
3 Demir M, Lang S, Schlattjan M, Drebber U, Wedemeyer I, Nierhoff D, Kaul I, Sowa J, Canbay A, Töx U, Steffen HM. NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. PLoS One 2013;8:e58360. [PMID: 23555578 DOI: 10.1371/journal.pone.0058360] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
4 Polyzos SA, Kountouras J, Slavakis A, Zafeiriadou E, Patsiaoura K, Katsiki E, Zavos C, Papatheodorou A, Terpos E. A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study. Biomarkers 2013;18:607-13. [DOI: 10.3109/1354750x.2013.838305] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
5 Bril F, Lomonaco R, Cusi K. The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. Clinical Lipidology 2012;7:471-81. [DOI: 10.2217/clp.12.47] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
6 Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(35): 12566-12573 [PMID: 25253959 DOI: 10.3748/wjg.v20.i35.12566] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
7 Boursier J, Rousselet M, Aubé C, Calès P. Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. Expert Opinion on Medical Diagnostics 2012;6:381-94. [DOI: 10.1517/17530059.2012.691878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
8 Boursier J, Calès P. Controlled attenuation parameter (CAP): a new device for fast evaluation of liver fat? Liver Int. 2012;32:875-877. [PMID: 22672640 DOI: 10.1111/j.1478-3231.2012.02824.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
9 Martini A, Fattovich G, Guido M, Bugianesi E, Biasiolo A, Ieluzzi D, Gallotta A, Fassina G, Merkel C, Gatta A, Negro F, Pontisso P. HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients. J Viral Hepat 2015;22:800-8. [DOI: 10.1111/jvh.12394] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
10 Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs. 2013;73:1-14. [PMID: 23329465 DOI: 10.1007/s40265-012-0004-0] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 11.7] [Reference Citation Analysis]
11 Mencin AA, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Pediatr Clin North Am. 2011;58:1375-1392, x. [PMID: 22093857 DOI: 10.1016/j.pcl.2011.09.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
12 Akiyama M. Identification of UACA, EXOSC9, and ΤΜX2 in bovine periosteal cells by mass spectrometry and immunohistochemistry. Anal Bioanal Chem 2014;406:5805-13. [PMID: 24696107 DOI: 10.1007/s00216-014-7673-3] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
13 Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther. 2012;36:815-823. [PMID: 22966992 DOI: 10.1111/apt.12046] [Cited by in Crossref: 119] [Cited by in F6Publishing: 124] [Article Influence: 13.2] [Reference Citation Analysis]
14 Mardinoglu A, Agren R, Kampf C, Asplund A, Uhlen M, Nielsen J. Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:3083. [PMID: 24419221 DOI: 10.1038/ncomms4083] [Cited by in Crossref: 304] [Cited by in F6Publishing: 263] [Article Influence: 43.4] [Reference Citation Analysis]
15 Caballería L, Saló J, Berzigotti A, Planas R, Vila C, Huertas C, Torres M, Torán P, Caballería J. Hígado graso no alcohólico. Documento de posicionamiento de la Societat Catalana de Digestologia. Gastroenterología y Hepatología 2014;37:372-83. [DOI: 10.1016/j.gastrohep.2014.03.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, Ortiz-Lopez C, Hecht J, Feldstein AE, Webb A, Louden C, Goros M, Tio F. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60:167-174. [PMID: 23973932 DOI: 10.1016/j.jhep.2013.07.042] [Cited by in Crossref: 154] [Cited by in F6Publishing: 138] [Article Influence: 17.1] [Reference Citation Analysis]
17 Houot M, Ngo Y, Munteanu M, Marque S, Poynard T. Systematic review with meta-analysis: Direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Aliment Pharmacol Ther. 2016;43:16-29. [PMID: 26516104 DOI: 10.1111/apt.13446] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 8.0] [Reference Citation Analysis]
18 Neal CP, Mann CD, Pointen E, Mcgregor A, Garcea G, Metcalfe MS, Berry DP, Dennison AR. Influence of Hepatic Parenchymal Histology on Outcome Following Right Hepatic Trisectionectomy. J Gastrointest Surg 2012;16:2064-73. [DOI: 10.1007/s11605-012-2008-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
19 Al-Humadi H, Alhumadi A, Al-Saigh R, Strilakou A, Lazaris AC, Gazouli M, Liapi C. "Extracellular matrix remodelling in the liver of rats subjected to dietary choline deprivation and/or thioacetamide administration". Clin Exp Pharmacol Physiol 2018;45:1245-56. [PMID: 30019784 DOI: 10.1111/1440-1681.13013] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Alkhouri N, Berk M, Yerian L, Lopez R, Chung YM, Zhang R, McIntyre TM, Feldstein AE, Hazen SL. OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci 2014;59:1617-24. [PMID: 24464211 DOI: 10.1007/s10620-014-3031-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
21 Sandboge S, Perälä M, Salonen MK, Blomstedt PA, Osmond C, Kajantie E, Barker DJP, Eriksson JG. Early growth and non-alcoholic fatty liver disease in adulthood—the NAFLD liver fat score and equation applied on the Helsinki Birth Cohort Study. Annals of Medicine 2013;45:430-7. [DOI: 10.3109/07853890.2013.801275] [Cited by in Crossref: 83] [Cited by in F6Publishing: 24] [Article Influence: 9.2] [Reference Citation Analysis]
22 Chapman A, El Miedany Y. Psoriasis. In: El Miedany Y, editor. Comorbidity in Rheumatic Diseases. Cham: Springer International Publishing; 2017. pp. 81-124. [DOI: 10.1007/978-3-319-59963-2_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
23 Demir M, Lang S, Nierhoff D, Drebber U, Hardt A, Wedemeyer I, Schulte S, Quasdorff M, Goeser T, Töx U, Steffen H. Stepwise Combination of Simple Noninvasive Fibrosis Scoring Systems Increases Diagnostic Accuracy in Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2013;47:719-26. [DOI: 10.1097/mcg.0b013e3182819a89] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
24 Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World J Gastroenterol 2014; 20(31): 10851-10863 [PMID: 25152587 DOI: 10.3748/wjg.v20.i31.10851] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 59] [Article Influence: 8.5] [Reference Citation Analysis]
25 De Ceuninck F, Kargar C, Ilic C, Caliez A, Rolin JO, Umbdenstock T, Vinson C, Combettes M, de Fanti B, Harley E, Sadlo M, Lefèvre AL, Broux O, Wierzbicki M, Fourquez JM, Perron-Sierra F, Kotschy A, Ktorza A. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol 2013;168:339-53. [PMID: 22925001 DOI: 10.1111/j.1476-5381.2012.02184.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
26 Markus MR, Baumeister SE, Stritzke J, Dörr M, Wallaschofski H, Völzke H, Lieb W. Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP). Arterioscler Thromb Vasc Biol. 2013;33:1690-1695. [PMID: 23685558 DOI: 10.1161/atvbaha.112.300556] [Cited by in Crossref: 36] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
27 Wang X, Li C, Muhammad I, Zhang X. Fatty acid composition in serum correlates with that in the liver and non-alcoholic fatty liver disease activity scores in mice fed a high-fat diet. Environmental Toxicology and Pharmacology 2016;44:140-50. [DOI: 10.1016/j.etap.2016.04.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
28 Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology. 2013;57:103-111. [PMID: 22930399 DOI: 10.1002/hep.26030] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 8.1] [Reference Citation Analysis]
29 Serviddio G, Blonda M, Bellanti F, Villani R, Iuliano L, Vendemiale G. Oxysterols and redox signaling in the pathogenesis of non-alcoholic fatty liver disease. Free Radical Research 2013;47:881-93. [DOI: 10.3109/10715762.2013.835048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
30 Delvin E, Patey N, Dubois J, Henderson M, Lévy É. Pediatric Non-Alcoholic Fatty Liver Disease. J Med Biochem 2015;34:3-12. [PMID: 28356817 DOI: 10.2478/jomb-2014-0059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
31 Polyzos SA, Kountouras J, Papatheodorou A, Katsiki E, Patsiaoura K, Zafeiriadou E, Zavos C, Papadopoulou E, Terpos E. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. Annals of Hepatology 2013;12:749-57. [DOI: 10.1016/s1665-2681(19)31316-x] [Cited by in Crossref: 23] [Article Influence: 2.6] [Reference Citation Analysis]
32 Bai Q, Zhang X, Xu L, Kakiyama G, Heuman D, Sanyal A, Pandak WM, Yin L, Xie W, Ren S. Oxysterol sulfation by cytosolic sulfotransferase suppresses liver X receptor/sterol regulatory element binding protein-1c signaling pathway and reduces serum and hepatic lipids in mouse models of nonalcoholic fatty liver disease. Metabolism 2012;61:836-45. [PMID: 22225954 DOI: 10.1016/j.metabol.2011.11.014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]